First-in-human study of the safety, pharmacokinetics, and

Limitations of Animal Studies for Predicting Toxicity in Clinical

Lipogenesis inhibitors: therapeutic opportunities and challenges

First-In-Human Clinical Trial Requirement -BioPharma Services

Frontiers Application of Pharmacokinetic-Pharmacodynamic

AdventHealth Research Institute

FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models

A first-in-human study to investigate the safety, tolerability

Biomolecules, Free Full-Text

Frontiers Prostate Cancer Progression: as a Matter of Fats